human colon cancer cell line ls174t  (ATCC)

Journal: ACS Omega

Article Title: Characterization of Structurally Diverse 18 F-Labeled d-TCO Derivatives as a PET Probe for Bioorthogonal Pretargeted Imaging

doi: 10.1021/acsomega.3c04597

Figure Lengend Snippet: (A) Procedure followed for the in vivo pretargeted blocking approach. (B) In vivo representative fluorescence image of TCO-Cy5 uptake in LS174T tumor-bearing mice. Images were acquired 24 h post-TCO-Cy5 injection, and the fluorescence signal was quantified as total efficiency. The white dashed line encircles the tumor. (C) Tumor uptake of TCO-Cy5 in vivo and ex vivo was expressed as total efficiency in the blocked group. Data were normalized to TCO-Cy5 uptake in positive and negative control groups. (mean ± SD, n = 4/group).

Article Snippet: The human colon cancer cell line LS174T (ATCC CL-188) was obtained from the ATCC.

Techniques: In Vivo, Blocking Assay, Fluorescence, Injection, Ex Vivo, Negative Control

Journal: ACS Omega

Article Title: Characterization of Structurally Diverse 18 F-Labeled d-TCO Derivatives as a PET Probe for Bioorthogonal Pretargeted Imaging

doi: 10.1021/acsomega.3c04597

Figure Lengend Snippet: (A) In vivo representative coronal μPET/CT image of LS174T tumor-bearing mice injected with [ 18 F]MICA-214 72 h post-CC49 (control) or CC49-Tz (pretargeted) injection. PET images represent the averaged tracer distribution from the dynamic scans (0–60 min). The white dashed lines encircle the tumor region, and the arrows represent the bladder (B), intestines (I), and liver (L). (B) Time–activity curve of tumor uptake of [ 18 F]MICA-214 in groups injected with CC49-Tz and control group injected with CC49 (0 to 60 min) (mean ± SD, n = 4/group). (C) Ex vivo biodistribution of LS174T tumor-bearing mice 60 min post tracer injection.

Article Snippet: The human colon cancer cell line LS174T (ATCC CL-188) was obtained from the ATCC.

Techniques: In Vivo, Injection, Activity Assay, Ex Vivo

Journal: American journal of surgery

Article Title: Anti-mucin 4 fluorescent antibody brightly targets colon cancer in patient-derived orthotopic xenograft mouse models: A proof-of-concept study for future clinical applications

doi: 10.1016/j.amjsurg.2022.05.036

Figure Lengend Snippet: MUC4 Western blotting of normal human colon, human colon cancer cell line (LS174T), and cancer lysates of patient-derived primary tumors (C4) and patient-derived metastatic tumors (Liver 2).

Article Snippet: Lysates were obtained from normal colon, colon cancer cell line LS174T (ATCC, Manassas, VA) xenografts, and patient-derived colon cancer xenografts.

Techniques: Western Blot, Derivative Assay

Journal: American journal of surgery

Article Title: Anti-mucin 4 fluorescent antibody brightly targets colon cancer in patient-derived orthotopic xenograft mouse models: A proof-of-concept study for future clinical applications

doi: 10.1016/j.amjsurg.2022.05.036

Figure Lengend Snippet: Orthotopic model of human cell line colon cancer tumor, LS174T, growing on the cecum (yellow arrow). (A) Bright light imaging demonstrating colonic tumor of approximately 6 mm in diameter (red bar represents 1 cm). (b) Fluorescence imaging after targeting with 50 μg of MUC4-IR800, 48 hours after administration.

Article Snippet: Lysates were obtained from normal colon, colon cancer cell line LS174T (ATCC, Manassas, VA) xenografts, and patient-derived colon cancer xenografts.

Techniques: Imaging, Fluorescence

Journal: American journal of surgery

Article Title: Anti-mucin 4 fluorescent antibody brightly targets colon cancer in patient-derived orthotopic xenograft mouse models: A proof-of-concept study for future clinical applications

doi: 10.1016/j.amjsurg.2022.05.036

Figure Lengend Snippet: Cross-sectional imaging of LS174T tumor (1 cm) 48 h after administration of 50 μg of MUC4-IR800. (a) Fluorescence imaging on LI-COR Odyssey of the transected tumor demonstrated the depth of penetration throughout the tumor. (b) Heat map imaging of fluorescence demonstrating the highest fluorescence signal at the periphery of the tumor with moderate signal throughout. (c) H&E imaging confirms the presence of colon cancer cells histologically (10x magnification).

Article Snippet: Lysates were obtained from normal colon, colon cancer cell line LS174T (ATCC, Manassas, VA) xenografts, and patient-derived colon cancer xenografts.

Techniques: Imaging, Fluorescence